Bradley R. Groveman

Key facts

• Affiliation in 2024 to 2026 papers is the Division of Intramural Research, Laboratory of Neurological Infections and Immunity, NIAID Rocky Mountain Laboratories, Hamilton, Montana; in 2021 it was the Laboratory of Persistent Viral Diseases at RML.
• Second author on the 2020 ring trial of second-generation RT-QuIC, in which CSF from 55 sCJD patients and 45 controls plus olfactory brushings gave 98 to 100 percent concordance across six laboratories.
• First author of the March 2021 Scientific Reports study showing iPSC-derived human cerebral organoids propagate CJD prions and that pentosan polysulfate slowed propagation both before and after infection, proposed as a human 3D drug-screening model.
• First author of a June 2024 Emerging Infectious Diseases study in which human cerebral organoids exposed to chronic wasting disease prions showed no human prion propagation, consistent with a strong species barrier.
• First author of a 2025 NPJ Dementia study in which sCJD and fatal familial insomnia prions infected organoids with strain traits preserved regardless of host genotype.
• Second author of an April 2024 PLoS Pathogens paper using RT-QuIC type assays to detect alpha-synuclein, tau and prion seeds on steel surfaces and surgical instruments.
• Coauthor of a July 2025 Lancet Neurology cohort study of 1,631 participants in which alpha-synuclein seed amplification kinetics predicted cognitive decline in Parkinson disease.
• Second author of a 2026 J Clin Invest organoid study distinguishing two sCJD subtypes by neuronal and neurotransmitter changes with shared mitochondrial deficits.
• Coauthor of a September 2026 Acta Neuropathologica review of Caughey's work on prion disease inhibitors, and first author of an October 2026 Acta Neuropathologica review of Caughey's RT-QuIC legacy.
• Coauthor of a March 2026 medRxiv preprint comparing brain-only and gut-only Lewy body pathology using immunohistochemistry and seed amplification assay.

Timeline

1. 2020Ann Clin Transl Neurol ring trial of second-generation RT-QuIC for sCJD.
2. 2021Scientific Reports first-author study on cerebral organoids as a CJD drug-screening model.
3. 2024PLoS Pathogens study on detecting misfolded protein seeds on solid surfaces.
4. 2024Emerging Infectious Diseases first-author study finding no CWD transmission to human organoids.
5. 2024PLoS One first-author study on bleach inactivation of human CJD prions.
6. 2025Lancet Neurology alpha-synuclein seed amplification kinetics cohort study.
7. 2025NPJ Dementia first-author study on FFI and sCJD prions in organoids listed in PubMed.
8. 2026J Clin Invest organoid study of two sCJD subtypes listed in PubMed.
9. 2026Coauthor of medRxiv preprint on brain-only versus gut-only synucleinopathy.
10. 2026Coauthor of Acta Neuropathologica review on Caughey's search for prion disease inhibitors.
11. 2026First-author Acta Neuropathologica review on Byron Caughey's RT-QuIC legacy listed in PubMed.